MW 390.5 Da, Purity >98%. Potent HMG-CoA reductase inhibitor. Proapoptotic, able to arrest cells in G1 by down-regulation of CDK4, CDK6 and cyclin D1 and up-regulation of p21 and p27.
Images
Publications
Filter by
- British journal of cancer 106:1689-962012The differential effects of statins on the metastatic behaviour of prostate cancer.Applications:Unspecified applicationReactive species:Unspecified reactive speciesM Brown,C Hart,T Tawadros,V Ramani,V Sangar,M Lau,N ClarkePubMed 22531631
- International journal of biological sciences 7:645-502011Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription.Applications:Unspecified applicationReactive species:Unspecified reactive speciesFuichi Yap et. al.PubMed 21647332
- Neuroscience letters 468:28-332009A role of nitric oxide in neurite outgrowth of neuroblastoma cells triggered by mevastatin or serum reduction.Applications:Unspecified applicationReactive species:Unspecified reactive speciesMaria Elephteria Evangelopoulos,Stefan Wüller,Joachim Weis,Alexander KrüttgenPubMed 19853642
- Carcinogenesis 22:1061-72001HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.Applications:Unspecified applicationReactive species:Unspecified reactive speciesA Wächtershäuser,B Akoglu,J SteinPubMed 11408350
Key facts
- CAS number
- 73573-88-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 390.5 Da
- Molecular formula
- C23H34O5
- PubChem identifier
- 64715
- Nature
- Synthetic
Target data
Alternative names
3 hydroxy 3 methylglutaryl CoA reductase, 3 hydroxymethylglutaryl CoA reductase, 3-hydroxy-3-methylglutaryl CoA reductase (NADPH), 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3H3M, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, AI838772, AIS, ANDR_HUMAN, AR, AR8, ASRT2, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, AW493413, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), BDPLT5, BRIC2, Bile salt export pump, Bsep, CD 87, CD87 antigen, Cytosolic NADP-isocitrate dehydrogenase, DHTR, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), EC 3.4.21.73, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ESRL 1, ESRR A, Epididymis luminal protein 216, Epididymis secretory protein Li 26, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen-related receptor alpha, Estrra, FLJ11090, G protein coupled receptor 154, G protein coupled receptor PGR14, G protein coupled receptor for asthma susceptibility, GPR 154, GPRA, HEL-216, HEL-S-26, HMDH_HUMAN, HMG CoAR, HMG-CoA reductase, HUMARA, HYSP1, Hydroxymethylglutaryl CoA reductase, ICDH, IDCD, IDH, IDH1, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, KD, Kennedy disease (KD), LDLCQ3, MGC103269, MGC104252, MGC112732, MO 3, MVTR, Monocyte activation antigen Mo3, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, NPSR, NR3B1, NR3C4, Neuropeptide S receptor, Neuropeptide S receptor 1, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Oxalosuccinate decarboxylase, PFIC 2, PGR 14, PGY4, PICD, PLAU, PLAUR, PLG, PLMN_HUMAN, Plasmin, Plasmin heavy chain A, Plasmin light chain B, Plasminogen, Plasminogen activator receptor urokinase, Plasminogen activator urokinase receptor, QPD, RP24-311F12.2, SBMA, SCAN1, SMAX1, Sister of P glycoprotein, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, TFM, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, U-plasminogen activator, UPA receptor, UPAM, UPAR_HUMAN, URK, URKR, Urinary plasminogen activator, Urinary plasminogen activator receptor, Urokinase plasminogen activator, Urokinase plasminogen activator receptor, Urokinase plasminogen activator surface receptor, Urokinase type plasminogen activator, VRR 1, Vasopressin receptor related receptor 1, androgen receptor splice variant 4b, estrogen receptor related receptor alpha, hERR1, nps receptor, progressive familial intrahepatic cholestasis 2, u plasminogen activator receptor, u-PA, u-plasminogen activator receptor form 2, urokinase-type plasminogen activator (uPA) receptor
Recommended products
MW 390.5 Da, Purity >98%. Potent HMG-CoA reductase inhibitor. Proapoptotic, able to arrest cells in G1 by down-regulation of CDK4, CDK6 and cyclin D1 and up-regulation of p21 and p27.
Key facts
- CAS number
- 73573-88-3
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 390.5 Da
- Molecular formula
- C23H34O5
- PubChem identifier
- 64715
- Nature
- Synthetic
- Solubility
Soluble in ethanol to 10 mM.
Soluble in DMSO to 100 mM.
- Biochemical name
- Mevastatin
- Biological description
Potent HMG-CoA reductase inhibitor. Proapoptotic, able to arrest cells in G1 by down-regulation of CDK4, CDK6 and cyclin D1 and up-regulation of p21 and p27.
- Canonical SMILES
- CCC(C)C(=O)OC1CCC=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O
- Isomeric SMILES
- CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O
- InChI
- InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1
- InChIKey
- AJLFOPYRIVGYMJ-INTXDZFKSA-N
- IUPAC name
- [(1S,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- +4°C
- Storage information
- Store under desiccating conditions, The product can be stored for up to 12 months
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Chemical Structure - Mevastatin, HMG-CoA reductase inhibitor (ab120652)
2D chemical structure image of ab120652, Mevastatin, HMG-CoA reductase inhibitor
Immunocytochemistry/ Immunofluorescence - Mevastatin, HMG-CoA reductase inhibitor (ab120652)
Anti-Cytochrome C antibody ab90529 staining cytochrome C in HepG2 cells treated with mevastatin (ab120652), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of mevastatin, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab120652 (mevastatin) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-Cytochrome C antibody ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com